Feedback received by the Institute of Clinical Effectiveness Research during this time will be evaluated and incorporated as seen fit, before the final changes are made to the framework.
The Institute for Clinical and Economic Research (ICER) has opened up its updated value framework for a 60-day public comment period. Feedback received by ICER during this time will be evaluated and incorporated as seen fit, before the final changes are made to the framework. ICER plans to use the final framework to guide its evidence assessment reports for the period between April 2017 and April 2019.
ICER is one of several organizations involved in the process of creating a value framework that can ultimately guide clinicians, payers, as well as patients make informed decisions on treatments and coverage. The motivation for developing this guidance, according to ICER’s president Steven Pearson, MD, MSc, FRCP, is the lack of discussions that connect drug efficacy with value—this led to ICER’s creation of a value-based price benchmark.
The following are a few of the updates proposed for the existing framework, which can be used across healthcare services, including drugs and devices, procedures, and delivery system interventions.
The complete report can be accessed here.
ICER’s claims that they are trying to create a non-biased framework. The updated proposal states that ICER does not intend to target any specific interest group, unlike the original framework that was aimed at health plans and payers.
The president of the National Pharmaceutical Council, Dan Leonard, said in a statement, “We recognize that developing frameworks is challenging and appreciate that ICER has made significant changes. We look forward to reviewing the updated framework in greater detail and understanding how these changes could work in practice.”